Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice

Y. Saikawa, T. Kubota, T. H. Kuo, Toshiharu Furukawa, S. Kase, H. Tanino, Y. Isobe, M. Watanabe, K. Ishibiki, M. Arimori, M. Kitajima

研究成果: Article

5 引用 (Scopus)

抄録

A new combined cancer chemotherapy regimen of mitomycin C (MMC) and cisplatin (DDP) showed synergistic antitumor activity against human gastric cancer xenografts St-40 and SC-1-NU in BALB/c nu/nu mice. The drugs were administered intraperitoneally at doses of 2 or 4 mg/kg for MMC and 3 or 6 mg/kg for DDP, respectively. To clarify the schedule-dependent antitumor activity of MMC and DDP against St-40 and SC-1-NU, different sequential therapies were conducted. Simultaneous administration of these agents showed the highest antitumor activity against SC1-NU among the three regimens used, whereas the sequence of MMC followed by DDP showed higher antitumor activity than the reverse sequence against St-40. The intratumoral concentration of platinum was significantly increased in St-40 treated with the sequence MMC to DDP, in comparison with the sequence DDP to MMC. The maximum tolerated dose (MTD) of this combination was 4 mg MMC plus 6 mg DDP per kg in all the combinations, and these MTDs were 2/3 of the corresponding values for their single use. Since this combination increased the antitumor activity of each single agent without any increase in their toxicity, it would appear to be useful clinically.

元の言語English
ページ(範囲)242-245
ページ数4
ジャーナルJournal of Surgical Oncology
56
発行部数4
DOI
出版物ステータスPublished - 1994

Fingerprint

Mitomycin
Combination Drug Therapy
Heterografts
Nude Mice
Cisplatin
Stomach Neoplasms
Maximum Tolerated Dose
Platinum
Human Activities
Appointments and Schedules
Drug Therapy
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

これを引用

Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice. / Saikawa, Y.; Kubota, T.; Kuo, T. H.; Furukawa, Toshiharu; Kase, S.; Tanino, H.; Isobe, Y.; Watanabe, M.; Ishibiki, K.; Arimori, M.; Kitajima, M.

:: Journal of Surgical Oncology, 巻 56, 番号 4, 1994, p. 242-245.

研究成果: Article

Saikawa, Y, Kubota, T, Kuo, TH, Furukawa, T, Kase, S, Tanino, H, Isobe, Y, Watanabe, M, Ishibiki, K, Arimori, M & Kitajima, M 1994, 'Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice', Journal of Surgical Oncology, 巻. 56, 番号 4, pp. 242-245. https://doi.org/10.1002/jso.2930560408
Saikawa, Y. ; Kubota, T. ; Kuo, T. H. ; Furukawa, Toshiharu ; Kase, S. ; Tanino, H. ; Isobe, Y. ; Watanabe, M. ; Ishibiki, K. ; Arimori, M. ; Kitajima, M. / Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice. :: Journal of Surgical Oncology. 1994 ; 巻 56, 番号 4. pp. 242-245.
@article{1137ea62bec540d1a02a76a443a6fc2b,
title = "Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice",
abstract = "A new combined cancer chemotherapy regimen of mitomycin C (MMC) and cisplatin (DDP) showed synergistic antitumor activity against human gastric cancer xenografts St-40 and SC-1-NU in BALB/c nu/nu mice. The drugs were administered intraperitoneally at doses of 2 or 4 mg/kg for MMC and 3 or 6 mg/kg for DDP, respectively. To clarify the schedule-dependent antitumor activity of MMC and DDP against St-40 and SC-1-NU, different sequential therapies were conducted. Simultaneous administration of these agents showed the highest antitumor activity against SC1-NU among the three regimens used, whereas the sequence of MMC followed by DDP showed higher antitumor activity than the reverse sequence against St-40. The intratumoral concentration of platinum was significantly increased in St-40 treated with the sequence MMC to DDP, in comparison with the sequence DDP to MMC. The maximum tolerated dose (MTD) of this combination was 4 mg MMC plus 6 mg DDP per kg in all the combinations, and these MTDs were 2/3 of the corresponding values for their single use. Since this combination increased the antitumor activity of each single agent without any increase in their toxicity, it would appear to be useful clinically.",
keywords = "cisplatin, gastric cancer, mitomycin C",
author = "Y. Saikawa and T. Kubota and Kuo, {T. H.} and Toshiharu Furukawa and S. Kase and H. Tanino and Y. Isobe and M. Watanabe and K. Ishibiki and M. Arimori and M. Kitajima",
year = "1994",
doi = "10.1002/jso.2930560408",
language = "English",
volume = "56",
pages = "242--245",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice

AU - Saikawa, Y.

AU - Kubota, T.

AU - Kuo, T. H.

AU - Furukawa, Toshiharu

AU - Kase, S.

AU - Tanino, H.

AU - Isobe, Y.

AU - Watanabe, M.

AU - Ishibiki, K.

AU - Arimori, M.

AU - Kitajima, M.

PY - 1994

Y1 - 1994

N2 - A new combined cancer chemotherapy regimen of mitomycin C (MMC) and cisplatin (DDP) showed synergistic antitumor activity against human gastric cancer xenografts St-40 and SC-1-NU in BALB/c nu/nu mice. The drugs were administered intraperitoneally at doses of 2 or 4 mg/kg for MMC and 3 or 6 mg/kg for DDP, respectively. To clarify the schedule-dependent antitumor activity of MMC and DDP against St-40 and SC-1-NU, different sequential therapies were conducted. Simultaneous administration of these agents showed the highest antitumor activity against SC1-NU among the three regimens used, whereas the sequence of MMC followed by DDP showed higher antitumor activity than the reverse sequence against St-40. The intratumoral concentration of platinum was significantly increased in St-40 treated with the sequence MMC to DDP, in comparison with the sequence DDP to MMC. The maximum tolerated dose (MTD) of this combination was 4 mg MMC plus 6 mg DDP per kg in all the combinations, and these MTDs were 2/3 of the corresponding values for their single use. Since this combination increased the antitumor activity of each single agent without any increase in their toxicity, it would appear to be useful clinically.

AB - A new combined cancer chemotherapy regimen of mitomycin C (MMC) and cisplatin (DDP) showed synergistic antitumor activity against human gastric cancer xenografts St-40 and SC-1-NU in BALB/c nu/nu mice. The drugs were administered intraperitoneally at doses of 2 or 4 mg/kg for MMC and 3 or 6 mg/kg for DDP, respectively. To clarify the schedule-dependent antitumor activity of MMC and DDP against St-40 and SC-1-NU, different sequential therapies were conducted. Simultaneous administration of these agents showed the highest antitumor activity against SC1-NU among the three regimens used, whereas the sequence of MMC followed by DDP showed higher antitumor activity than the reverse sequence against St-40. The intratumoral concentration of platinum was significantly increased in St-40 treated with the sequence MMC to DDP, in comparison with the sequence DDP to MMC. The maximum tolerated dose (MTD) of this combination was 4 mg MMC plus 6 mg DDP per kg in all the combinations, and these MTDs were 2/3 of the corresponding values for their single use. Since this combination increased the antitumor activity of each single agent without any increase in their toxicity, it would appear to be useful clinically.

KW - cisplatin

KW - gastric cancer

KW - mitomycin C

UR - http://www.scopus.com/inward/record.url?scp=0028040945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028040945&partnerID=8YFLogxK

U2 - 10.1002/jso.2930560408

DO - 10.1002/jso.2930560408

M3 - Article

C2 - 8057650

AN - SCOPUS:0028040945

VL - 56

SP - 242

EP - 245

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -